DEXILANT SOLUTAB - (30MG ; TABLET,ORALLY DISINTEGRATING,DELAYED RELEASE)

Generic Name	DEXLANSOPRAZOLE	**Innovator**	Takeda
Dosage	30MG ; TABLET,ORALLY DISINTEGRATING,DELAYED RELEASE	**Branded US Sales**	Less Than $1000 mn
Probable FTF	None	**Known Para IV Filers**	None
Other ANDA developers	None	**Tentative Approvals**	None
Final Approvals	None	**Generic Launches**	None
Indication	DEXILANT SoluTab delayed-release orally disintegrating tablets (DEXILANT SoluTab) are indicated in patients 12 years of age and older for: • Maintenance of healed EE and relief of heartburn. • Treatment of symptomatic non-erosive GERD.		
Complexities	Yes		

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.

Executive Summary

Please Contact contact@researchdelta.com to get Detailed Information.

Patent Status

Please Contact contact@researchdelta.com to get Detailed Information.

Launch Timelines and Competition

Please Contact contact@researchdelta.com to get Detailed Information.

Chronology Of Events

Please Contact contact@researchdelta.com to get Detailed Information.